Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral ...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an announcement.

Scientists are uncovering new insights into the mechanisms driving neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These fatal diseases ...

Early in his career he devised a contraption capable of distinguishing certain mineral signatures underground, and he later took part in one of the high adventures of Canada’s storied mining history ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.LOS ANGELES - (NewMediaWire) - - Clene (NASDAQ: CLNN) ...

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to ...

The Centers for Medicare & Medicaid Services (CMS) has announced a first-of-its-kind directive requiring Medicare Advantage plans to approve coverage for Qalsody, a treatment for people living with ...

Correspondence to Dr Ruben P A van Eijk, Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands; R.P.A.vanEijk-2{at}umcutrecht.nl ALSFRS and ...